Exagen is a life sciences company focused on advancing the diagnosis, prognosis, and management of autoimmune conditions through innovative testing solutions. Their flagship AVISE testing platform utilizes Cell-Bound Complement Activation Products (CB-CAPs) technology, which identifies specific biomarkers associated with systemic lupus erythematosus (SLE). This technology leverages the stability of CB-CAPs, which are hydrolyzed complement activation products bound to circulating cells, allowing for more reliable and accurate diagnostics. The AVISE tests, including AVISE Lupus and AVISE CTD, are designed to provide physicians with critical insights into patient conditions, enhancing the ability to monitor and treat autoimmune diseases effectively.

In addition to their diagnostic capabilities, Exagen emphasizes a robust research and development framework that integrates advanced data analytics and bioinformatics. Their team employs comprehensive statistical analysis and machine learning techniques to interpret complex biological datasets, facilitating personalized medicine approaches. With a substantial data portfolio that includes over 1.5 million analyzed data points from a diverse patient population, Exagen is positioned to drive innovation in autoimmune disease management and improve patient outcomes through evidence-based insights and tailored therapeutic strategies.

United States

Exagen Inc. is a Patient Focused, Discovery Driven, CLIA-certified, CAP-accredited laboratory with a growing menu of proprietary, internally developed tests focusing in the area of Rheumatology and Autoimmune diseases. Committed to Personalized Medicine, our AVISE tests are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management.

Exagen

Company Details